LONDON-Oxford BioMedica Plc, a gene therapy company spun from Oxford University, has announced they are making progress in an anti-cancer vaccine.
TroVax, designed to stimulate a patient's immune system to destroy cancer cells, has been tested in phase1/11 studies. Patients involved in the study did develop an immune response against a tumor antigen in colorectal cancer. The vaccine works by encoding the protein OBA1, which naturally exists on the surface of many tumor cells, and basically teaching the immune system to fight these protein cells when they are recognized.
People involved in the study were divided into three dosage groups of the vaccine. The first study's results are from the low dosage group, with the other reports expected to be published next year.
While officials from the company are optimistic the vaccine will be successful, they also warn that it has not yet been shown to treat human cancer.
Information from www.givenimaging.com, Reuters Health
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.